ANGLE PLC S/ADR - ANPCY STOCK NEWS

ANGLE plc announces a peer-reviewed study from Edith Cowan University demonstrating the effectiveness of the Parsortix system in isolating circulating tumor cells (CTCs) in ovarian cancer patients. The study shows a significant correlation between PD-L1 expression and CTCs undergoing epithelial to mesenchymal transition (EMT). Among 16 patients, 63% had detectable CTCs, with 50% being PD-L1 positive. The results suggest that using the Parsortix system could enhance patient selection for immunotherapy, addressing the need for improved treatment outcomes where current response rates are low.

ANGLE plc announced a groundbreaking study establishing the concordance of its Parsortix liquid biopsy blood test with invasive tissue biopsy in metastatic breast cancer (MBC) patients. Conducted by experts at the University of Southern California, the study indicates that over 50% of MBC patients are unable to undergo successful tissue biopsies due to various factors. With a pilot study involving 19 patients, the Parsortix test demonstrated high concordance in RNA sequencing results, potentially offering a non-invasive alternative to guide treatment decisions effectively. This research contributes significant insights into cancer monitoring and personalized therapy.

ANGLE plc (AIM:AGL)(OTCQX:ANPCY) has updated on its laboratory accreditation and ovarian cancer study. The company has submitted its accreditation requests for its clinical laboratories in the US and UK. However, supply chain issues have delayed the analysis of ovarian cancer study samples, now expected to finalize in H1 2022. Despite these challenges, ANGLE remains optimistic about obtaining FDA clearance for its Parsortix system, designed to harvest cancer cells from blood, while continuing discussions with the FDA regarding its regulatory decision.

ANGLE plc announced significant findings from a study on non-small cell lung cancer (NSCLC) patients with EGFR mutations treated with Osimertinib. The research, led by Prof. Evi Lianidou, highlights the importance of analyzing both circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) for understanding drug resistance mechanisms. The study revealed elevated DNA methylation in cancer-related genes at disease progression, suggesting a link between these alterations and Osimertinib resistance. Liquid biopsies offer safer, cost-effective longitudinal monitoring of cancer evolution, supporting precision medicine initiatives.

ANGLE plc (OTCQX:ANPCY) has announced the issuance of 6,666 new ordinary shares following the exercise of employee options. These shares will rank equally with existing shares, expanding the total to 235,143,050 shares. An application for admission to trading on AIM has been made, expected to take effect on December 30, 2021. The company is recognized for its innovative liquid biopsy technology, particularly the Parsortix system, which captures circulating tumor cells for various analyses, showcasing a commitment to advancing cancer diagnostics and treatment.

ANGLE plc (OTCQX: ANPCY) announced the issuance of 20,000 new ordinary shares following the exercise of employee options, raising the total number of shares to 235,136,384. These shares will commence trading on the London Stock Exchange's AIM on December 7, 2021. The shares rank equally with existing shares. ANGLE focuses on liquid biopsy solutions with its Parsortix system, which captures circulating tumor cells for analysis, supporting advances in cancer diagnostics.

ANGLE plc announces the publication of research from the Medical University of Vienna, demonstrating the effectiveness of its Parsortix system in analyzing circulating tumor cells (CTCs) in non-small cell lung cancer (NSCLC) patients. The study reveals that CTCs with cancer stem cell properties correlate with worse patient outcomes. The Parsortix system achieves a capture rate of up to 80%, surpassing competing systems, and supports RNA analysis for prognostic purposes. The research underscores the potential of CTCs in clinical management and drug discovery.

ANGLE plc announced the issuance of 50,000 new ordinary shares following the exercise of employee options. This move will increase the total number of ordinary shares to 235,116,384. The new shares are set to be admitted to trading on AIM, with the start date expected to be December 2, 2021. ANGLE's Parsortix® system, a key technology for liquid biopsy, is under FDA review for use in metastatic breast cancer patients, while a successful clinical study for an ovarian cancer triage test showed remarkable 95.1% accuracy.

ANGLE plc (OTCQX:ANPCY) has issued 22,667 new ordinary shares following the exercise of employee options, increasing its total shares to 235,066,384. These shares will rank equally with existing shares, and trading is set to commence on November 23, 2021. The company is known for its liquid biopsy technologies, specifically the Parsortix system, which harvests circulating tumor cells (CTCs) for cancer analysis. ANGLE's advancements in cancer diagnostics and established collaborations with renowned medical institutions support its innovative approaches in healthcare.